Advancing the science of precision medicine through data
Foundation Medicine provides genomic data solutions to accelerate and de-risk precision oncology development with our biopharma partners. Biopharma companies can extract key insights from our database to:
Identify or validate novel targets and pathways
Discover and refine biomarkers to stratify patients
Inform trial design and indication selection
Calculate prevalence to understand commercial potential and strategy
With over 400,000 patient profiles, FoundationCore is one of the largest databases of real-world comprehensive genomic profiling results in oncology. It’s also constantly evolving, typically adding more than 2,000 samples per week and has updated analyses and new biomarkers added to existing samples.
In addition to deep information on genomic alterations, computational biomarkers such as tumor mutational burden (TMB) and microsatellite instability (MSI) status are available, as are PD-L1 results.
FoundationCore is pan-tumor and pan-center, providing a breadth of quality results from our validated tests (including the FDA-approved FoundationOne®CDx).
Based on Data from FoundationCore
FoundationInsights is a web-based application that provides partners with flexible access to FoundationCore data via user-friendly, self-serve queries.
Ask our data anything: Analyze genomic data and extract powerful insights with one of the largest databases of real-world genomic profiles coupled with a powerful analytics platform. FoundationInsights can help provide answers to drive your goals.
Customized Genomic Analyses
Ask experts from the Cancer Genomic Research team for support with complex analyses. Deep collaborative interrogation of genomic data can include fields not currently reported clinically, such as loss of heterozygosity, somatic/germline zygosity, and novel and customized signatures.
Important Safety Information
FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com.